| |
|
|
Session 67
Poster Presentations Therapy Experienced Patients Wednesday 1:30 - 3:30 pm Hall A |
| 565 | Response to LPVr in Experienced Patients: Effect of a Treatment Interruption R Haubrich*1, B Best1, C Miller1, M Witt3, C Kemper4, K Squires5, C Diamond6, P Heseltine7, N Hellmann8, A Rigby1, E Capparelli1, JA McCutchan1, California Collaborative Treatment Group (CCTG) 1Univ of Southern California, San Diego; 3Harbor-UCLA, Torrance, CA; 4Santa Clara Valley Med Ctr, San Jose, CA; 5Univ of Southern California at Los Angeles; 6Univ of California-Irvine, CA; 7Quest Diagnostics, San Juan Capistrano, CA; and 8ViroLogic, San Francisco, CA |
| 566 | Dual Therapy with Indinavir/Ritonavir 800/100 mg BID and Efavirenz 600 mg QD Effectively Treats Patients with Combination Nucleoside Analogue Failure: HIV-NAT 009 48-week Analysis M. Boyd*1,2, C. Duncombe1,2, P. Srasuebkul1,3, E. Hassink1,4, N. Chomchey1,3, T. Methanukroh1,3, S. Ubolyam1,3, K. Ruxrungtham1,5, M. Stek6, J. Lange1,4, D. Cooper1,2, P. Phanuphak1,5 1HIV Netherlands Australia Thailand Res Collaboration; 2Thailand NCHECR, Univ of New South Wales, Australia; 3Thai Red Cross AIDS Res Ctr, Bangkok; 4Thailand IATEC, Univ of Amsterdam, The Netherlands; 5Thailand Chulalongkorn Univ; and 6Merck and Co, Whitehouse Station, NJ |
| 568 | Summary of Pooled Efficacy and Safety Analyses of Enfuvirtide Treatment for 24 Weeks in TORO 1 and TORO 2 Phase III Trials in Highly Antiretroviral Treatment-experienced Patients J.-F. Delfraissy*1, J. Montaner2, J. Eron3, R. DeMasi4, J. Chung5, C. Drobnes4, J. Delehanty4, M. Salgo5, , , , , , 1; ; ; ; ; ; ; 1Hosp Bicêtre, Paris, France; 2Univ of British Columbia, Vancouver, Canada; 3Univ of North Carolina, Chapel Hill; 4Trimeris Inc, Durham, NC; and 5Hoffmann-La Roche, Inc, Nutley, NJ |
| 567 | Response to a Second Treatment Regimen Following Virologic Failure M. Fischl*1, H. Ribaudo2, A. Collier3, J. Feinberg4, N. Rajicic2, A. Erice5 1Univ of Miami, FL; 2Harvard Sch of Public Hlth, Boston, MA; 3Univ of Washington, Seattle; 4Univ of Cincinnati, OH; and 5Hosp Asepeyo, Madrid, Spain |